DrugDashboards

K Phos Neutral

Sodium Phosphate, Dibasic, Anhydrous, Potassium Phosphate, Monobasic, and Sodium Phosphate, Monobasic, Monohydrate · SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg/1; POTASSIUM PHOSPHATE, MONOBASIC 155 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1 · Tablet, Coated · Oral · Beach Products, Inc.

NDC 00486-1125-05 · 500 TABLET, COATED in 1 BOTTLE · UNAPPROVED DRUG OTHER · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has jumped 61% in a year, to $0.3144 per unit — sharp rises like this often mean supply is already tightening. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4Nov 2013Sep 2026$0.3144
154 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$9.43
#90 count
$28.29

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$975
42 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic, and sodium phosphate, monobasic, monohydrate (oral solid) in the next 90 days

price up 66% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Sodium Phosphate, Dibasic, Anhydrous, Potassium Phosphate, Monobasic, and Sodium Phosphate, Monobasic, Monohydrate (Tablet, Coated)

LabelerStrengthFirst seenLast seen
Beach Products, Inc.SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg/1; POTASSIUM PHOSPHATE, MONOBASIC 155 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1Aug 26, 2026Sep 2, 2026
Beach Products, Inc.SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 155 mg/1; POTASSIUM PHOSPHATE, MONOBASIC 852 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1Jul 22, 2026Aug 19, 2026
Beach Products, Inc.POTASSIUM PHOSPHATE, MONOBASIC 155 mg/1; SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "K Phos Neutral — NDC 00486-1125-05," retrieved September 3, 2026, https://drugdashboards.com/drug/00486112505.

Free to cite with attribution — see how the data is put together.